Mabion S.A. (MAB.WA)
PLN 9.49
(-4.33%)
PLN 9.49
(-4.33%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 208.25 Million PLN | 11.86% |
| 2022 | 186.17 Million PLN | 1.05% |
| 2021 | 184.23 Million PLN | 135.23% |
| 2020 | 78.32 Million PLN | -31.02% |
| 2019 | 113.54 Million PLN | -21.54% |
| 2018 | 144.71 Million PLN | 75.53% |
| 2017 | 82.44 Million PLN | -9.65% |
| 2016 | 91.24 Million PLN | -52.86% |
| 2015 | 193.54 Million PLN | -86.93% |
| 2014 | 1.48 Billion PLN | 96.26% |
| 2013 | 754.68 Million PLN | -80.97% |
| 2012 | 3.96 Billion PLN | 14620.07% |
| 2011 | 26.94 Million PLN | 14.95% |
| 2010 | 23.43 Million PLN | 6632.39% |
| 2009 | 348.14 Thousand PLN | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 213.91 Million PLN | 2.72% |
| 2024 Q3 | 179.34 Million PLN | -8.67% |
| 2024 Q2 | 196.36 Million PLN | -8.21% |
| 2023 Q4 | 208.25 Million PLN | -9.63% |
| 2023 Q3 | 230.44 Million PLN | 31.89% |
| 2023 FY | 208.25 Million PLN | 11.86% |
| 2023 Q1 | 198.59 Million PLN | 6.67% |
| 2023 Q2 | 174.72 Million PLN | -12.02% |
| 2022 FY | 186.17 Million PLN | 1.05% |
| 2022 Q4 | 186.17 Million PLN | -13.18% |
| 2022 Q3 | 214.44 Million PLN | 38.84% |
| 2022 Q2 | 154.45 Million PLN | -7.97% |
| 2022 Q1 | 167.83 Million PLN | -8.91% |
| 2021 Q4 | 184.23 Million PLN | -4.1% |
| 2021 Q3 | 192.12 Million PLN | -15.52% |
| 2021 Q2 | 227.41 Million PLN | 6.6% |
| 2021 FY | 184.23 Million PLN | 135.23% |
| 2021 Q1 | 213.34 Million PLN | 172.39% |
| 2020 Q1 | 99.64 Million PLN | -12.24% |
| 2020 FY | 78.32 Million PLN | -31.02% |
| 2020 Q2 | 87.03 Million PLN | -12.65% |
| 2020 Q3 | 80.61 Million PLN | -7.38% |
| 2020 Q4 | 78.32 Million PLN | -2.85% |
| 2019 Q3 | 107.59 Million PLN | -8.78% |
| 2019 Q4 | 113.54 Million PLN | 5.53% |
| 2019 Q2 | 117.95 Million PLN | -8.06% |
| 2019 Q1 | 128.29 Million PLN | -11.35% |
| 2019 FY | 113.54 Million PLN | -21.54% |
| 2018 Q3 | 154.26 Million PLN | -9.83% |
| 2018 FY | 144.71 Million PLN | 75.53% |
| 2018 Q4 | 144.71 Million PLN | -6.19% |
| 2018 Q2 | 171.07 Million PLN | -34.51% |
| 2018 Q1 | 261.2 Million PLN | 216.82% |
| 2017 FY | 82.44 Million PLN | -9.65% |
| 2017 Q1 | 89.78 Million PLN | -1.61% |
| 2017 Q2 | 108.73 Million PLN | 21.11% |
| 2017 Q3 | 90.14 Million PLN | -17.09% |
| 2017 Q4 | 82.44 Million PLN | -8.54% |
| 2016 FY | 91.24 Million PLN | -52.86% |
| 2016 Q2 | 203.71 Million PLN | 2.98% |
| 2016 Q3 | 215.19 Million PLN | 5.63% |
| 2016 Q4 | 91.24 Million PLN | -57.6% |
| 2016 Q1 | 197.81 Million PLN | 2.21% |
| 2015 FY | 193.54 Million PLN | -86.93% |
| 2015 Q4 | 193.54 Million PLN | 8.78% |
| 2015 Q3 | 177.93 Million PLN | 8.6% |
| 2015 Q2 | 163.83 Million PLN | 5.98% |
| 2015 Q1 | 154.59 Million PLN | -89.56% |
| 2014 FY | 1.48 Billion PLN | 96.26% |
| 2014 Q4 | 1.48 Billion PLN | 916.1% |
| 2014 Q2 | 121.74 Million PLN | 53.84% |
| 2014 Q1 | 79.13 Million PLN | -89.51% |
| 2014 Q3 | 145.77 Million PLN | 19.74% |
| 2013 Q1 | 38.33 Million PLN | -99.03% |
| 2013 Q2 | 73.04 Million PLN | 90.52% |
| 2013 Q3 | 72.72 Million PLN | -0.44% |
| 2013 Q4 | 754.68 Million PLN | 937.75% |
| 2013 FY | 754.68 Million PLN | -80.97% |
| 2012 Q4 | 3.96 Billion PLN | 0.0% |
| 2012 FY | 3.96 Billion PLN | 14620.07% |
| 2012 Q3 | - PLN | 0.0% |
| 2011 FY | 26.94 Million PLN | 14.95% |
| 2010 FY | 23.43 Million PLN | 6632.39% |
| 2009 FY | 348.14 Thousand PLN | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioceltix S.A. | 12.73 Million PLN | -1535.251% |
| BIOTON S.A. | 822.22 Million PLN | 74.672% |
| Captor Therapeutics Spolka Akcyjna | 97.29 Million PLN | -114.046% |
| Molecure S.A. | 168.57 Million PLN | -23.536% |
| NanoGroup S.A. | 8.63 Million PLN | -2312.697% |
| Pharmena S.A. | 24.13 Million PLN | -762.979% |
| Poltreg S.A. | 127.09 Million PLN | -63.853% |
| Pure Biologics Spólka Akcyjna | 22.73 Million PLN | -815.885% |
| Ryvu Therapeutics S.A. | 403.2 Million PLN | 48.35% |
| Synthaverse S.A. | 265.9 Million PLN | 21.68% |
| Urteste S.A. | 29.59 Million PLN | -603.608% |